Ann: Strategic Partnership for Clinical R&D in China worth $4M, page-16

Massive EOFY sell down means this stock's mkt cap not remotely reflective of its earning potential. Look at its global sales footprint. A trickle of small partnerships are beginning to emerge in its various locations. These will only increase. Its had great sales growth, but off a very small base. You know the superiority of its products to standard in the market. Its going to be decades before it competes with the big boys (unless it gets a partnership) as some on here have rightly pointed out in the past.

But it only has to be taking 0.5%, 1%, 2%, then 3% of the global market in the next decade and it will be massive vs its silly pocket change mkt cap. I only hope they negotiate partnerships rather than getting taken over. Built a big position recently below 10 cents and will gladly build more if it gets sold back down there.